beta-D-Ribofuranose 1,2,3,5-tetraacetate

We are beta-D-Ribofuranose 1,2,3,5-tetraacetate CAS:13035-61-5 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:beta-D-Ribofuranose 1,2,3,5-tetraacetate
CAS.NO:13035-61-5
Synonyms:1,2,3,5-Tetra-O-acetyl-β-D-ribofuranose
β-D-Ribofuranose1,2,3,5-tetraacetate
1,2,3,5-Tetra-O-Acetyl-D-Ribose
β-D-Ribofuranose 1,2,3,5-Tetraacetate
Tetra-O-acetyl-β-D-ribofuranose
Molecular Formula:C13H18O9
Molecular Weight:318.27700
 
Physical and Chemical Properties:
Density:1.29
Melting point:81-83ºC
Boiling point:385.6ºC
Flash point:168.5ºC
 
Specification:
Appearance:White to off-white crystalline powder
Assay(HPLC):≥98.0%
Loss on drying:≤0.5%
Residue on ignition:≤0.1%
Heavy metal:≤20ppm
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Applicationd in the synthesis of 3-(β-D-ribofuranosyl)-2,3-dihydro-6H-1,3-oxazine-2,6-dione, a new pyrimidine nucleoside analog related to uridine.

beta-D-Ribofuranose 1,2,3,5-tetraacetate


Related News: “CAR T-cell therapy continues to deliver remarkable outcomes for patients with hematologic malignancies, and next-generation approaches are needed to enable broad and timely patient access and reduce the cost and complexity of therapy,” said Scott Wolchko, President and Chief Executive Officer of Fate Therapeutics.2-Ethyl-3-methoxypyrazine CAS:25680-58-4 “Once these risks have been identified then a project team can be put together combining the necessary expertise to provide the integrated services and tailored support to ensure continuity of supply from beginning to end.”1-cloro-9-bromodecano CAS:/ The foundational patent, which expires in 2034, is owned by MSK and is licensed exclusively to Fate Therapeutics for all human therapeutic uses.1,3-diisopropilcarbodiimida CAS:693-13-0 Process: The importance of safety is obvious. The research and development of specialty drug substances (especially high-barrier generic drug substance drugs) usually need to avoid the original process patents, and some chemicals are developed because of the complex structure or the harsh synthetic conditions The synthetic route is more difficult, so the importance of process design capabilities of API companies is becoming more important.An effective treatment for Alzheimer’s, which is estimated in 60%-70% of around 50 million dementia cases worldwide, could become one of the best-selling drugs globally.

Related Products
Product Name
(4S,5R)-3-Benzoyl-2-(4-methoxyphenyl)-4-phenyloxazolidine-5-carboxylic acid View Details
Secretin Acetate View Details
Hexapeptide-9 View Details
2-Bromo-9,9-diphenyl-9H-fluorene manufacturer 3′-Amino-2′-hydroxyacetophenone hydrochloride manufacturer 2-Deoxy-2,2-difluoro-D-erythro-pentafuranous-1-ulose-3,5-dibenzoate manufacturer MOG (35-55) manufacturer 3,5-Dimethylbenzoic acid manufacturer